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(adjusted OR, 0.53; 95% CI, 0.29-0.99) were associated with amore profound protec-
tive effect than those prescribed 0.45 DDD (adjusted OR, 0.88; 95% CI, 0.52-1.51).
The longest continuous use of statins (265 days) was found to have the greatest
protective effect (adjusted OR, 0.57; 95% CI, 0.34-0.95) among all of the examined
durations. CONCLUSIONS:Any use of statins was associated with a reduced risk of
COPD exacerbation, and the protective effect was further enhanced as statins pre-
scribed more currently, at a higher average daily dose or for a longer duration. Use
of statins might be considered for preventing COPD exacerbations.
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OBJECTIVES:Waterpipe smoking has emerged as a new trend of tobacco use with
growing popularity especially among adolescents and young adults. Our objectives
were to determine the predictors of having an intention to quit waterpipe smoking
among University of Houston students who smoked awaterpipe in the pastmonth
(N276). METHODS: Cross-sectional study through an online survey in February
2011. Questions included demographics (gender, age, race/ethnicity), tobacco use
history (waterpipes, cigarettes, and cigars), perception of risk, and perceived social
acceptability of waterpipe smoking. The survey also inquired about characteristics
of tobacco waterpipe users such as the age and place of starting the waterpipe
smoking, ownership of a waterpipe, frequency and duration of waterpipe smoking
sessions, as well as willingness to quit. Descriptive statistics and chi-square anal-
yses were used to determine the frequencies and associations of participant char-
acteristics and multivariate logistic regression models were carried out to deter-
mine predictors of having an intention to quit. RESULTS:Most of the sample (83%)
reported no intention to quit. Participants who believed that waterpipe smoking
was harmful to one’s healthweremore likely to have a desire to quit (OR2.38, 95%
CI1.05-5.36). Participants with Indian or Pakistani descent were more likely to
have an intention to quit compared to white participants (OR4.74, 95% CI1.61-
13.93). Those who smoked waterpipe for more than 60 minutes were less likely to
have a desire to quit (OR0.29, 95% CI0.12-0.73). CONCLUSIONS: Findings dem-
onstrate a low level of a desire to quit among waterpipe smokers and underscore
the urgent need to develop interventions that educate waterpipe smokers about
the expected harms of continued use. This may increase the desire to quit and the
odds of a successful cessation thereafter.
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OBJECTIVES: Waterpipe smoking is an understudied form of tobacco use with
growing popularity among college students and amisconception of relative safety.
Our objectives were to identify predictors of persistent waterpipe smoking among
college students who have tried using a waterpipe to smoke tobacco in the past.
The participants of our study included a sample of University of Houston (UH)
students who previously used awaterpipe to smoke tobacco (N1,141).METHODS:
Cross-sectional study through a voluntary online survey in February 2011. Survey
questions included demographics (gender, age, race/ethnicity), tobacco use, risk
perception, social acceptability, and popularity of waterpipe smoking. Two out-
come variables were identified in this study: outcome 1: monthly waterpipe smok-
ing ormore versus less thanmonthly use, outcome 2:weeklywaterpipe smoking or
more versus less frequent use. Descriptive statistics and chi-square analyses were
used to determine the frequencies and associations of participant characteristics
and multivariate logistic regression models were carried out to determine predictors
of persistent waterpipe use. RESULTS: Among those who previously used a water-
pipe, approximately one fifth reported smoking a waterpipe on a monthly basis or
more, and 5% reported smoking on aweekly basis ormore. Significant predictors of
persistentwaterpipe use included:WhiteMiddle-Eastern ethnicity, IndianAsian or
Pakistani Asian ethnicity, past 30-day cigar use, ownership of a waterpipe, believ-
ing waterpipe smoking was cool, and longer than 30 minutes waterpipe smoking
sessions. Those who believed that waterpipe smoking was harmful to one’s health
and those who thought government should evaluate the safety before selling the
waterpipes were less likely to become persistent users. CONCLUSIONS: Findings of
this study highlight the importance of developing interventions that address the
predictors identified. Educational programs that explain the potential harms of
waterpipe smoking and modify the cool image associated may be effective in pre-
venting the spread of this rapidly emerging health hazard.
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OBJECTIVES: Palivizumab given monthly prior to and throughout the RSV season
reduces incidence of RSV hospitalization (RSV-H) in premature infants, infants
with chronic lung disease of prematurity (CLDP), and children with hemodynami-
cally significant congenital heart disease (CHD). This study determines the impact
of non-compliance with palivizumab dosing and risk of RSV-H among Medicaid-
insured infants. METHODS: Infants with prematurity [34 weeks’ gestational age
(wGA)], CLDP and/or CHD born and discharged between May 1 and September 30
whoreceived1doseofpalivizumabduring theirfirstRSVseason (October1 -April 30)
were identified retrospectively in Medicaid claims data from 12 states. Palivizumab
compliance (first dose by November 30,5 consecutive doses during the RSV season,
and no gaps 35 days between consecutive doses) was evaluated across 6 seasons
(2003-2009). The percentage of infants with in-season RSV-H was calculated for non-
compliantandcompliant cohorts. Logistic regressionofRSV-Hwasperformed, adjust-
ing for non-compliance, wGA, birthweight, comorbidities, and other demographic/
clinical characteristics. RESULTS: A total of 8443 high-risk infants received 1 dose
of palivizumab. Approximately 67% of all infants were non-compliant. The per-
centage of infants with RSV-H was significantly higher among non-compliant vs.
compliant infants (12.0% vs. 7.4%, P0.001). In the logistic regression model, non-
compliant compared to compliant infants had a 1.31 (95% CI 1.18, 1.46) increased
odds of RSV-H, and odds were also higher for males, rural residents, capitated
healthplan members, infants who required neonatal intensive care at birth, gesta-
tional age 32 weeks or unknown (vs. 33-34 weeks), age 3 months at season
onset, and comorbidities (including CLDP/CHD) or emergency room/hospitaliza-
tion prior to first dose (all P0.001). CONCLUSIONS: Non-compliance with palivi-
zumab was common and significantly increased the risk of RSV-H in this Medicaid
population. Intervention strategies are needed to improve palivizumab adminis-
tration among Medicaid infants prior to and throughout the RSV season.
RESPIRATORY-RELATED DISORDERS – Cost Studies
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FEDERATION
Kulikov A, Komarov I
I.M. Sechenov First Moscow State Medical University, Moscow, Russia
OBJECTIVES: To estimate the budget impact of the inclusion of tiotropiumbromide
compared to ipratropium bromide on the top of standard COPD treatment scheme
with long-acting bronchodilators.METHODS: The one-year budget impact analysis
was conducted. Direct expenses associatedwith COPD exacerbations and resulting
follow-up costs were calculated using general tariff agreement of Russian obliga-
tory insurance system and official national statistics. For reference, accepted ex-
change rate was 1 EUR 40 RUB. RESULTS: Tiotropium bromide inclusion into the
standard COPD therapy provided cost saving benefits compared with inclusion of
ipratropium bromide in the COPD standard therapy scheme. Total costs of COPD
therapy were approximately 259,730 RUB (6,493 EUR) per patient in tiotropium
bromide group and 266,887 RUB (6,672 EUR) per patient in ipratropium bromide
groupwithin one year. Treatment of COPD using standard therapywith tiotropium
bromide inclusion compared to onewith ipratropiumbromide leads to cost savings
of 7,157 RUB (179 EUR) per patient-year. CONCLUSIONS: The results of budget
impact analysis illustrate that including tiotropium bromide into the standard
therapy of COPD instead of ipratropium bromide has potential to reduce Russian
health care system total costs for COPD treatment.
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Chronic obstructive pulmonary disease (COPD) is an increasing cause of morbi-
mortality in adults worldwide with a heavy economic burden on society. The in-
troduction of indacaterol, a neweffective long acting beta agonist, justifies a budget
impact analysis from the Colombian Health-Care System perspective.
OBJECTIVES: To develop a budget impact analysis, for five years, of the indacaterol
introduction in the Colombian Health-Care System.METHODS:Using the perspec-
tive of the Colombian Health-care System, we designed a budget impact model to
compare costs with and without the introduction of indacaterol for patients with
COPD GOLD stages II-III-IV. Clinical data and prevalence were obtained from pub-
lished literature. Basal maintenance treatment costs were calculated according to
GOLD guidelines consumption patterns and exacerbation costs were collected
from university hospital registries. A probabilistic Montecarlo sensitivity analysis
was performed. RESULTS: Total annual net costs (year 1-year 5) for the scenario
without indacaterol were: USD $40.123.556, $40.591.558, $41.056.575, $ 1.531.189
and $42.011.289. In the indacaterol scenario net costs were: $ 41.743.333, $
38.772.406, $ 38.862.224, $ 38.838.471 and $ 38.797.766. CONCLUSIONS:Under these
assumptions the progressive introduction of indacaterol in Colombian health care
system implies budgetary savings.
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OBJECTIVES: The private health care system in Brazil currently assists 47,008,888
individuals in Brazil. This study has the objective of evaluating the cost-effective-
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